Answers are grounded in this paper and cite their sources.
Demonstrates diagnostic performance of fluid tau biomarkers in Alzheimer's disease, suggesting new avenues for early intervention.
The introduction of blood-based biomarkers (BBMs) for Alzheimer’s disease (AD) represents one of the most transformative advances in neurodegenerative disease research over the past decade.1,2 For the first time, biological evidence of AD pathology can be obtained through a minimally invasive, scalable blood test, opening new opportunities for early diagnosis, patient triage, and implementation of disease-modifying therapies.3 Among the available biomarkers, phosphorylated tau (p-tau) species, particularly plasma p-tau217, have consistently shown excellent diagnostic performance across the AD continuum, recently culminating in regulatory approval of plasma p-tau217-based assays in both the USA and Europe.
No takes yet. Share an insight, caveat, or question.
Parnetti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: